Home
  >  
Section 52
  >  
Chapter 51,740

B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen

Mandal, P.K.; Dolai, T.K.; Bagchi, B.; Ghosh, M.K.; Bose, S.; Bhattacharyya, M.

Indian Journal of Pediatrics 81(10): 1092-1094

2014

ISSN/ISBN: 0973-7693
PMID: 24562617
DOI: 10.1007/s12098-013-1336-9
Accession: 051739418
Download citation:  
Text
  |  
BibTeX
  |  
RIS
Non-Hodgkin lymphoma associated with pregnancy is rare. Rituximab based chemotherapy is now considered the standard of care and considered safe for the treatment of diffuse large B-cell lymphoma (DLBCL) during pregnancy but little is known about its safety profile on the fetus. A 32 y primigravida was diagnosed as DLBCL at 20 wk of gestation. She received rituximab containing chemotherapy with successful pregnancy outcome. Though the baby was absolutely healthy, B-cell was totally absent in the cord blood.

PDF emailed within 0-6 h: $19.90




Related References

Schwarzbich, M.-A.; Schöning, T.; Cremer, M.; Lisenko, K.; Ho, A.D.; Witzens-Harig, M. 2016: Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment Leukemia and Lymphoma 57(7): 1723-1726
Wu, H.-J.; Zhang, Q.-Y.; Chen, D.-F.; Guan, X.-J.; Zhang, B.-L.; Ma, J. 2005: Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma Ai Zheng 24(12): 1498-1502
Yang, S.-H.; Lin, L.-W.; Fang, Y.-J.; Cheng, A.-L.; Kuo, S.-H. 2012: Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma Annals of Hematology 91(2): 291-294
Xu, W.; Li, J.-Y.; Zhang, Z.-H.; Qiu, H.-X.; Qian, S.-X.; Wu, H.-X.; Lu, H.; Sheng, R.-L. 2008: Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(4): 933-937
Hu, R.-H.; Sun, W.-L.; Zhao, H.; Hui, W.-H.; Guo, Y.-X.; Wan, S.-G.; Su, L. 2016: Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases Nan Fang Yi Ke da Xue Xue Bao 36(9): 1291-1294
Li, Y.; Yimamu, M.; Wang, X.; Zhang, X.; Mao, M.; Fu, L.; Aisimitula, A.; Nie, Y.; Huang, Q. 2014: Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression International Journal of Hematology 99(1): 79-86
Machida, S.; Tomizawa, D.; Tamaichi, H.; Okawa, T.; Endo, A.; Imai, K.; Nagasawa, M.; Morio, T.; Mizutani, S.; Takagi, M. 2013: Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab Journal of Pediatric Hematology/Oncology 35(6): 482-485
Lefrère, F.ço.; Bastit-Barrau, D.; Hequet, O.; Bourin, P.; Mathieu-Nafissi, S.; Bohbot, A.; Tilly, H.é; Salles, G.; Fermé, C.; Lapierre, V.ér.; Fornecker, L.; Micléa, J.-M.; Isebaert, L.; Bologna, S.; Fitoussi, O.; Mounier, N.; Haioun, C. 2013: Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients Transfusion 53(1): 115-122
Reddy, N.M.; Hernandez-Ilizaliturri, F.J.; Olejniczak, S.; Knight, J.; Czuczman, M.S. 2016: Rituximab resistance and its association with changes in the internal domain of CD20 antigen and down-regulation of pro-apoptotic protein Bax and Bak in both rituximab-resistant cell lines (RRCL) and diffuse large B-cell lymphoma (DLBCL) patient (pt) samples Journal of Clinical Oncology 24(18_Suppl): 17509-17509
Kasahara, S.; Hara, T.; Tsurumi, H.; Goto, N.; Kitagawa, J.-I.; Kanemura, N.; Yoshikawa, T.; Goto, H.; Fukuno, K.; Yamada, T.; Sawada, M.; Takahashi, T.; Takami, T.; Moriwaki, H. 2011: Phase Ii study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma Leukemia and Lymphoma 52(4): 629-634
Kang, G.W.; Kang, H.J.; Shin, D.-Y.; Gu, H.R.; Choi, H.S.; Lim, S.M. 2013: Radioimmunotherapy with (131)i-rituximab in a patient with diffuse large B-cell lymphoma relapsed after treatment with (90)y-ibritumomab tiuxetan Nuclear Medicine and Molecular Imaging 47(4): 281-284
Sikkema, T.; Schuiling, W.J.; Hoogendoorn, M. 2013: Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma BMJ Case Reports
Barton, S.; Hawkes, E.A.; Cunningham, D.; Peckitt, C.; Chua, S.; Wotherspoon, A.; Attygalle, A.; Horwich, A.; Potter, M.; Ethell, M.; Dearden, C.; Gleeson, M.; Chau, I. 2015: Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma European Journal of Haematology 94(3): 219-226
Voigtländer, C.; Harrer, T.; Schneider, L.; Schulze-Koops, H.; Niedobitek, G.; Lüftl, M. 2005: Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab International Journal of Dermatology 44(11): 976-978
Jang, G.; Yoon, D.H.; Kim, S.; Lee, D.H.; Lee, S.-W.; Huh, J.; Suh, C. 2011: Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma Korean Journal of Hematology 46(2): 103-110
Suzuki, T.; Kumagai, T.; Kitano, A.; Kubo, H.; Tabata, M.; Kimura, Y.; Miura, O.; Imai, Y. 2007: Pure red cell aplasia successfully treated with rituximab in a patient with relapsed diffuse large B-cell lymphoma Japanese Journal of Clinical Hematology 48(1): 67-70
Kaur, A.; Abughanimeh, O.; Zafar, Y.; Pluard, T. 2019: Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen Cureus 11(1): E3814
Kim, Y.S.; Ji, J.H.; Ko, Y.H.; Kim, S.J.; Kim, W.S. 2014: Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP Acta Haematologica 131(3): 156-161
Belada, D.; Smolej, L.ás.; Stepánková, P.; Králícková, P.ín.; Freiberger, T.ás. 2010: Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy Leukemia Research 34(9): E232-E234
Smith, S.E.; Toor, A.; Klein, J.; Rodriguez, T.; Stiff, P.J. 2016: The combination of gallium nitrate, rituximab and dexamethasone is effective and safe as a salvage regimen for diffuse large B-cell lymphoma Journal of Clinical Oncology 24(18_Suppl): 17510-17510